COPD Studies

Phase Ib Study – MN-221-CL-010

Phase Ib Study – MN-221-CL-010

In March 2010, we announced final results from a Phase Ib clinical trial (MN-221-CL-010) evaluating MN-221 in 48 moderate-to-severe COPD patients who received a one (1) hour intravenous infusion of MN-221 at three different escalating dose levels (300 micrograms, 600 micrograms, or 1200 micrograms) or placebo. Based on preliminary findings, all doses of MN-221 produced a clinically significant improvement in FEV(1)(L) as compared to the baseline and placebo. At the end of the one hour infusion, FEV(1)(L) increased as compared to baseline by an average of 21.5% (p=0.0025) for the 1200 microgram dose, 16.2% (p=0.020) for the 600 microgram dose, and 9.2% (p=NS) for the 300 microgram dose compared to a decrease of 4.0% for the placebo. MN-221 was well tolerated by all patients who received infusions of MN-221.

Continue Reading About Phase Ib Study – MN-221-CL-012